Multiple Myeloma section

Multiple Myeloma News & Features

Carfilzomib Improves OS vs Bortezomib in R/R Multiple Myeloma

Carfilzomib Improves OS vs Bortezomib in R/R Multiple Myeloma

Carfilzomib significantly prolonged overall survival compared with bortezomib in patients with relapsed or refractory multiple myeloma.

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

Earlier and Later Adult BMI Associated With Multiple Myeloma Risk

Younger and usual adult body mass index (BMI) may be linked to increased risk for developing multiple myeloma, research indicates.

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome

Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.

BBD Regimen Efficacious as First-line Therapy for Myeloma

BBD Regimen Efficacious as First-line Therapy for Myeloma

Bendamustine, bortezomib, and dexamethasone is efficacious and tolerable as first-line therapy for patients with myeloma ineligible to receive high-dose therapy.

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

Kd Superior to Vd in R/R Myeloma Regardless of Cytogenetic Risk

Results are presented from the phase 3 ENDEAVOR trial, which demonstrated the effect of carfilzomib plus dexamethasone (Kd) vs bortezomib plus dexamathasone (Vd) on risk of disease progression or death in patients with relapsed or refractory multiple myeloma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs